Nabilone Decreases Marijuana Withdrawal and a Laboratory Measure of Marijuana Relapse
Margaret Haney, Ziva D Cooper, Gillinder Bedi, Suzanne K Vosburg, Sandra D Comer, Richard W Foltin
Neuropsychopharmacology | NATURE PUBLISHING GROUP | Published : 2013
Awarded by US National Institute on Drug Abuse (NIDA)
The US National Institute on Drug Abuse (NIDA) supported this research (DA09236) and supplied the marijuana cigarettes. We are grateful to Laura Rolfe, Christina Hadzitheodorou, and Ashley Danies for their expert assistance in data collection and to Dr Adam Bisaga for medical supervision of the study.Dr Haney's research is funded by NIDA. She and Dr Foltin have received partial salary support for an investigator-initiated study from Astra-Zeneca. Dr Haney has also served as a consultant for GW Pharmaceuticals. Dr Comer has received partial salary support from investigator-initiated studies supported by Reckitt-Benckiser Pharmaceuticals, Schering-Plough Corporation, Johnson & Johnson Pharmaceutical Research & Development, Endo Pharmaceuticals, and MediciNova. In addition, she and Dr Vosburg have received compensation from Grunenthal GmbH to conduct a meta-analysis of drug-induced subjective responses. Dr Comer has also served as a consultant to the following companies: Analgesic Solutions, BioDelivery Sciences International, Cephalon, Inflexxion, Innovative Science Solutions, Janssen, King, Neuromed, Pfizer, and Salix. Drs Cooper and Bedi declare no potential conflicts of interest.